Lung Non-Small Cell Carcinoma with Genetic Abnormalities

Lung Non-Small Cell Carcinoma with Genetic Abnormalities — Trials · CancerIndex

Clinical trials

Registered studies

31 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 10
Recruiting: 5
Ph III recruiting: 0
Growth YoY: —
Industry share: 50%
Top sponsor: Guangdong Association of Clinical Trials
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (5)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03131206	A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer	terminated	Phase 1 / Phase 2	5	Dana-Farber Cancer InstituteOTHER	1	Sep 27, 2021	clinicaltrials
NCT02258607	Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase	terminated	Phase 1	21	Sierra Oncology LLC - a GSK companyINDUSTRY	1